<DOC>
	<DOCNO>NCT01082510</DOCNO>
	<brief_summary>The purpose prospective randomize control study prove non-inferiority UFT maintenance therapy BCG maintenance therapy prevent recurrence superficial bladder cancer .</brief_summary>
	<brief_title>Study Efficacy Maintenance Therapy Using Uracil-tegafur ( UFT ) Bacille Calmette-Guerin ( BCG ) Prevention Recurrences Superficial Bladder Cancer ( EMBARK Study )</brief_title>
	<detailed_description>Patients undergone transurethral resection superficial bladder tumor ( TUR-Bt ) BCG induction therapy eligible enrollment study . In principle , BCG induction therapy consist successive weekly intravesical administration 81 mg BCG-Connaught strain 80 mg BCG-Japan strain 6 week completion TUR-Bt . The patient randomly assign BCG maintenance therapy arm UFT maintenance therapy arm . The patient BCG maintenance therapy arm treat 3 successive weekly intravesical administration BCG 3 , 6 , 12 18 month start BCG induction therapy . The dosage BCG use BCG maintenance therapy use BCG induction therapy . Patients UFT maintenance therapy arm treat oral administration 400 mg UFT everyday three year end BCG induction therapy . The primary endpoint study three-year relapse-free survival rate .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Superficial bladder cancer Completion transurethral resection bladder tumor ( TURBt ) Completion BCG induction therapy TURBt . In principle , BCG induction therapy consist successive weekly intravesical administration 81 mg BCGConnaught strain 80 mg BCGJapan strain 6 week completion TURBt . Age 20 80 year ECOG performance status 0 1 Bladder capacity ≥ 150 mL Capable oral UFT administration Expected life prognosis ≥ 3 year Hematopoietic WBC ≥ 3,000/mm^3 Neutrophil ≥ 1,500/mm^3 Platelet ≥ 100,000/mm^3 Hepatic AST ALT ≤ 2 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL Hemoglobin ≤ 9.0 g/dL Creatinine ≤ 1.5 mg/dL Bladder cancer locate prostatic part urethra Anamnesis bladder cancer classify cT2 , cT3 cT4 Anamnesis metastatic bladder cancer Anamnesis upper urinary tract carcinoma situ Anamnestic treatment intravesical BCG administration within previous 6 month Prior anticancer chemotherapy radiotherapy Severe complication Presence contraindication administration BCG UFT Pregnancy , lactation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>UFT</keyword>
	<keyword>BCG</keyword>
</DOC>